Corcept Therapeutics (CORT) Revenue (2016 - 2025)
Historic Revenue for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $207.6 million.
- Corcept Therapeutics' Revenue rose 1374.56% to $207.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $741.2 million, marking a year-over-year increase of 1791.68%. This contributed to the annual value of $675.0 million for FY2024, which is 3994.09% up from last year.
- Per Corcept Therapeutics' latest filing, its Revenue stood at $207.6 million for Q3 2025, which was up 1374.56% from $194.4 million recorded in Q2 2025.
- In the past 5 years, Corcept Therapeutics' Revenue registered a high of $207.6 million during Q3 2025, and its lowest value of $79.4 million during Q1 2021.
- For the 5-year period, Corcept Therapeutics' Revenue averaged around $130.8 million, with its median value being $117.7 million (2023).
- As far as peak fluctuations go, Corcept Therapeutics' Revenue plummeted by 1481.01% in 2021, and later surged by 4768.97% in 2024.
- Corcept Therapeutics' Revenue (Quarter) stood at $98.8 million in 2021, then increased by 4.28% to $103.1 million in 2022, then surged by 31.39% to $135.4 million in 2023, then soared by 34.33% to $181.9 million in 2024, then grew by 14.16% to $207.6 million in 2025.
- Its Revenue was $207.6 million in Q3 2025, compared to $194.4 million in Q2 2025 and $157.2 million in Q1 2025.